Baucus health plan would mandate gifts disclosure

Share this article:
Baucus health plan would mandate gifts disclosure
Baucus health plan would mandate gifts disclosure
The healthcare plan unveiled by Sen. Max Baucus yesterday would require disclosure of “gifts and other transfers of value” from drug and device manufacturers to healthcare professionals.

As part of its call for increased transparency to lower costs, Baucus' “Call to Action” states: “Only with [disclosures] can potential bias be known. And the requirement to disclose may deter inappropriate behavior. Disclosure is the only way to know if there are inappropriate influences on the delivery of care and use of taxpayer dollars.”

The call for disclosure of industry-physician relationships comes amid a larger push for transparency to lower costs, and includes nods to recent AMA and PhRMA code revisions, last week's MedPac report, which endorsed stringent disclosure policies for drug, device and biologics manufacturers, and laws enacted in four states – Minnesota, Vermont, Maine and West Virginia – requiring that manufacturers report any cash or in-kind payments to physicians.

“Unfortunately, data collection alone may not prevent inappropriate relationships,” the white paper advises. “However, once national, system-wide data is available, the extent of industry influence and the wasteful spending that it leads to can be better determined. With this information, stronger enforcement can be put into place, so that regardless of provider relationships, we can be sure physicians are recommending and performing medical care based on sound medical science rather than heavy-handed industry influence.”

The plan, which represents the opening salvo in the Democrats' healthcare reform efforts, is a fairly generic one, similar to those proposed by Sen. Clinton and President-elect Obama during the Democratic primary -- apart from making insurance mandatory, which is where Clinton (for) and Obama (against) differed. Baucus, a moderate Democrat from Montana, chairs the Senate Finance Committee, which has held nine hearings on healthcare reform this year.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...